We develop, manufacture and market non-invasive cancer tests
Nucleix Ltd. develops, manufactures and markets highly innovative and non-invasive molecular cancer diagnostic tests. Our highly sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix technology is based on a combination of a new biochemical platform in conjunction with sophisticated algorithms.
Our first product, Bladder EpiCheck, is an IVD urine test for detection of bladder cancer that can reduce follow up cystoscopies, with the highest performance in the market. This test has shown NPV of 99%, sensitivity of 92% and a specificity of 88%, in a large multi-center, prospective and blinded study